Review of imaging techniques for evaluating morphological and functional responses to the treatment of bone metastases in prostate and breast cancer

• J. Orcajo Rincon ^[5] ; J. Muñoz Langa ^[6] ; J. M. Sepúlveda Sánchez ^[7] ; G. C. Fernández Pérez ^[1] ; M. Martínez ^[2] ; E. Noriega Álvarez ^[8] ; S. Sanz Viedma ^[3] ; J. C. Vilanova ^[4] ; A. Luna ^[9]
  1. [1] Hospital Universitario Pío del Río Hortega

     Hospital Universitario Pío del Río Hortega

     Valladolid, España

     
  2. [2] Hospital del Mar

     Hospital del Mar

     Barcelona, España

     
  3. [3] Hospital Universitario Virgen de la Victoria

     Hospital Universitario Virgen de la Victoria

     Málaga, España

     
  4. [4] Universitat de Girona

     Universitat de Girona

     Gerona, España

     
  5. [5] Nuclear Medicine Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
  6. [6] Medical Oncology, Hospital Dr. Arnau de Vilanova, Valencia, Spain
  7. [7] Medical Oncology, Hospital Universitario, 12 de Octubre, Madrid, Spain
  8. [8] Nuclear Medicine, General University Hospital of Ciudad Real, Ciudad Real, Spain
  9. [9] Radiology, HT médica, Clínica Las Nieves, Calle Carmelo Torres, 2, 23007 Jaén, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 7, 2022, págs. 1290-1310
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Bone metastases are very common complications associated with certain types of cancers that frequently negatively impact the quality of life and functional status of patients; thus, early detection is necessary for the implementation of immediate therapeutic measures to reduce the risk of skeletal complications and improve survival and quality of life. There is no con- sensus or universal standard approach for the detection of bone metastases in cancer patients based on imaging. Endorsed by the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Medical Radiology (SERAM), and the Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM) a group of experts met to discuss and provide an up-to-date review of our current understanding of the biological mechanisms through which tumors spread to the bone and describe the imaging methods available to diagnose bone metastasis and monitor their response to oncological treatment, focusing on patients with breast and prostate cancer. According to current available data, the use of next-generation imaging techniques, including whole-body diffusion-weighted MRI, PET/CT, and PET/MRI with novel radiopharmaceuticals, is recommended instead of the classical combination of CT and bone scan in detection, staging and response assessment of bone metastases from prostate and breast cancer.